The anticoagulants market size is estimated to be USD 35,475.2 million in 2022 and is expected to witness a CAGR of 10.35% during the forecast period 2023-2033. The increasing use of new oral anticoagulants (NOACs), growing incidence of cardiovascular diseases and venous thromboembolism (VTE), rising unmet requirements, escalating number of obese and old persons, and a surge in demand for innovative therapies are factors contributing to the market growth. However, the increased cost of NOACs, increased risk of adverse effects, absence of NOAC countermeasures, and strict regulatory environment are expected to hinder growth.

Segmentation

By Application

On the basis of application, the market is segmented into stroke, atrial fibrillation & heart attack, pulmonary embolism (PE), deep vein thrombosis (DVT), and others. In 2022, the atrial fibrillation & heart attack segment held the highest market share owing to the growing usage of anticoagulants in the treatment of various disorders and a sizable target population.

By Route of Administration

Based on route of administration, the market is bifurcated into injectable anticoagulants and oral anticoagulants. In 2022, the oral anticoagulants segment held the highest market share owing to technical improvements in anticoagulants, and their significant risk-reduction impact.

By Drug Class

On the basis of drug class, the market is segregated into vitamin k antagonists, heparin & LMWH, NOACs, and others. In 2022, the NOACs segment held the highest market share owing to the increasing use of NOACs in comparison to warfarin, and NOACs provide a number of benefits over warfarin.

By Distribution Channel

Based on distribution channel, the market is divided into online pharmacy, hospital pharmacy, retail pharmacy. In 2022, the hospital pharmacy segment held the highest market share owing to the fact that it offers a number of advantages, including better access to medications.

Regional Markets

In 2022, North America region accounted for the highest revenue in the anticoagulants market and is expected to maintain its dominance during the forecast period. This is attributed to the expanding R&D initiatives, rising knowledge and widespread occurrence of risk factors like diabetes and obesity in the populace, regional introductions of new products, and the increased incidence of cardiovascular conditions that need anticoagulants for treatment. However, the Asia-Pacific region is predicted to grow at the fastest rate during the projection period owing to the increasing frequency of cardiovascular diseases, growing knowledge of cardiovascular diseases, surging regional disposable incomes, and acceptance of advanced blood thinners.

Competitor Insights

Some of the key players operating in the anticoagulants market are Sanofi S.A. (France), Portola Pharmaceuticals, Inc. (US), Pfizer, Inc. (US), Johnson & Johnson (US), GlaxoSmithKline plc. (UK), Daiichi Sankyo Company Limited (Japan), Bristol-Myers Squibb Company (US), Boehringer Ingelheim GmbH (Germany), Bayer AG (Germany), and Aspen Holdings (South Africa).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including application, route of administration, drug class, and distribution channel from 2023 to 2033.

Report Scope:

Segmentation: Anticoagulants Market Report 2022 – 2033

Application (Revenue, USD Million), 2022 – 2033

• Stroke
• Atrial fibrillation & heart attack
• Pulmonary embolism (PE)
• Deep vein thrombosis (DVT)
• Others

Route of Administration (Revenue, USD Million), 2022 – 2033

• Injectable anticoagulant
• Oral anticoagulant

Drug Class (Revenue, USD Million), 2022 – 2033

• Vitamin K Antagonist
• Heparin & LMWH
• NOACs
  • Pradaxa
  • Savaysa & lixiana
  • Eliquis
  • Xarelto
  • Bevyxxa
• Others

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA